Clinical trial
Study of AT-101 in Combination With Topotecan in Relapsed/Refractory Small Cell…
NCT00397293 · Ascenta Therapeutics, Industry · Completed
Key facts
| NCT number | NCT00397293 |
|---|---|
| Title | Study of AT-101 in Combination With Topotecan in Relapsed/Refractory Small Cell Lung Cancer |
| Official title | An Open-label, Multicenter, Phase I/II Study of AT-101 in Combination With Topotecan in Patients With Relapsed or Refractory Small Cell Lung Cancer After Prior Platinum Containing First Line Chemotherapy |
| Lead sponsor | Ascenta Therapeutics, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | AT-101, topotecan |
| Enrollment | 36 |
| Start date | Nov 1, 2006 |
| Primary completion | Dec 1, 2008 |
| Completion | Dec 1, 2008 |
| First posted | Nov 9, 2006 |
| Last update posted | Aug 24, 2010 |
| Countries | Russia, Ukraine, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: